Transmission of sarcoidosis via cardiac transplantation

Burke, William M.; Keogh, Anne; Maloney, Peter; Delprado, Warick; Bryant, David; Spratt, P.

doi:10.1016/0140-6736(90)93354-r

Cited by 97 publications

(35 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seasonal clusterings of sarcoidosis in the months of June and July [61], time and space clusters [62,63], an increased incidence in health workers [64] and the transmission of sarcoidosis by transplants [65] have been observed and further support the hypothesis of transmissible sarcoid-inducing agents. For example, Borrelia burgdorferi has recently been proposed as a possible cause of sarcoidosis [66,67], although data obtained by the author's group do not support this hypothesis [68].…”

Section: Aetiologymentioning

confidence: 53%

“…Conversely, in two out of four cases patients receiving a lung or other organs from a donor who had a spontaneous remission of sarcoidosis in the past were observed to develop sarcoid-like lesions without suffering from sarcoidosis [73]. Others report the transmission of sarcoidosis by cardiac transplant [65]. These observations suggest that the aetiological agent hides within the lung and/or other compartments of the body.…”

Section: Aetiologymentioning

confidence: 97%

See 1 more Smart Citation

Sarcoidosis: immunopathogenetic concepts and their clinical application

1998

View full text Add to dashboard Cite

Our understanding of the immunopathogenesis of sarcoidosis has been advanced by studies of bronchoalveolar lavage cells. Activated macrophages and T-cells have been identified in different compartments of the sarcoid lung and the characteristics of the activation suggest that the cells become activated in the course of a normal immune response. The immune cells communicate via a cytokine network and the measuring of cytokine levels yields subgroups of sarcoidosis patients with different courses of the disease indicating different states of activation of the disease-mediating immune cells. The causative agent of sarcoidosis has not yet been identified; however, some of the described mechanisms can be clinically applied either to detect patients at risk of deterioration or to develop new therapeutic strategies. Using these approaches methotrexate, pentoxifylline and thalidomide have been identified as drugs which effectively suppress sarcoid inflammation and the serum level of soluble interleukin-2 receptors has been delineated to be a serum marker of sarcoid inflammation. Furthermore, analysing the pulmonary cytokine network in sarcoidosis will yield new staging parameters possibly supplying prognostic information and guiding therapeutic intervention.

show abstract

Section: Aetiologymentioning

confidence: 53%

Section: Aetiologymentioning

confidence: 97%

Sarcoidosis: immunopathogenetic concepts and their clinical application

1998

View full text Add to dashboard Cite

show abstract

“…Apart from cases among blood relatives, some authors have observed aggregation among nonconsanguineous relatives [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] and timespace and seasonal clusters [10,11,[16][17][18][19][20][21][22] attributing these observations to environmental etiological factors, probably of an infectious nature. Studies based on experiments done with animals [23,24] and on observations in humans [25] appear to corroborate the transmissibility of the disease, although no unequivocal proof has been found of any causal agent. The infectious etiology is currently under research with the use of techniques for amplification and hybridization of nucleic acids [26][27][28][29].…”

Section: Introductionmentioning

confidence: 90%

Sarcoidosis: Family Contact Study

Fité

Alsina²,

Antó³

et al. 1998

Respiration

View full text Add to dashboard Cite

Aim: To assess the familial aggregation in sarcoidosis in our environment. Methods: The medical centers of Catalonia (Spain) were approached to identify, retrospectively, patients diagnosed as sarcoidosis from 1986 to 1988. 245 sarcoidosis cases were recorded (annual incidence: 1.36/100,000 inhabitants). Finally, in 1990 a telephone questionnaire was administered to 188 sarcoidosis cases. Results: These cases reported 3,757 familial contacts, 5 of whom had confirmed sarcoidosis. The clinical presentation of familial sarcoidosis was similar to nonfamilial sarcoidosis, only Löfgren syndrome stood out. The prevalence of sarcoidosis among familial contacts was 1.33/1,000. Conclusions: The familial association is low and corresponds with the low annual incidence in our community.

show abstract

“…Low-doses of steroids can prevent recurrence of the disease [2]. On the other hand sarcoidosis can be transmitted to the recipient by a donor heart [36].…”

Section: Heart Transplantationmentioning

confidence: 99%

Cardiac sarcoidosis – management and prognosis (RCD code: III-3A.3)

Błaut-Jurkowska

Kaźnica-Wiatr²,

Knap³

et al. 2017

Journal of Rare Cardiovascular Diseases

View full text Add to dashboard Cite

Sarcoidosis is a systemic, granulomatous disease of unknown etiology. Cardiac involvement in the course of sarcoidosis occurs in 5% of patients. However, about 25% of patient with systemic/pulmonary sarcoidosis might present with asymptomatic myocardial injury. The main manifestations of cardiac sarcoidosis are conduction abnormalities, ventricular arrhythmias and heart failure. Diagnosis of cardiac sarcoidosis remains a challenge for physicians. Treatment should be introduced at the time of diagnosis to prevent potentially lethal progression of cardiac disease. Steroids are the first drugs of choice. Additional anti-sarcoidosis agents are used as alternatives or to reduce the steroids dose. Some patients require implantation of a cardioverter-defibrillator for the prevention of sudden cardiac death. Patients with refractory ventricular tachyarrhythmia or severe, intractable heart failure unresponsive to optimal pharmacotherapy, require heart transplantation. Prognosis in cardiac sarcoidosis is highly variable, dependent on location and severity of heart involvement. This article reviews current diagnostic and therapeutic recommendations for cardiac sarcoidosis. JRCD 2017; 3 (2): 37-43

show abstract

Transmission of sarcoidosis via cardiac transplantation

Cited by 97 publications

References 3 publications

Sarcoidosis: immunopathogenetic concepts and their clinical application

Sarcoidosis: immunopathogenetic concepts and their clinical application

Sarcoidosis: Family Contact Study

Cardiac sarcoidosis – management and prognosis (RCD code: III-3A.3)

Contact Info

Product

Resources

About